7.025
price down icon3.84%   -0.275
 
loading
Schlusskurs vom Vortag:
$7.30
Offen:
$7.27
24-Stunden-Volumen:
9.34M
Relative Volume:
0.25
Marktkapitalisierung:
$7.25B
Einnahmen:
$113.29M
Nettoeinkommen (Verlust:
$-351.47M
KGV:
-18.02
EPS:
-0.3898
Netto-Cashflow:
$-309.19M
1W Leistung:
+5.41%
1M Leistung:
-19.03%
6M Leistung:
+177.47%
1J Leistung:
+148.06%
1-Tages-Spanne:
Value
$7.00
$7.63
1-Wochen-Bereich:
Value
$6.88
$7.85
52-Wochen-Spanne:
Value
$1.83
$12.43

Immunitybio Inc Stock (IBRX) Company Profile

Name
Firmenname
Immunitybio Inc
Name
Telefon
(844) 696-5235
Name
Adresse
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
Mitarbeiter
691
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
IBRX's Discussions on Twitter

Compare IBRX vs VRTX, REGN, ARGX, ALNY, INSM

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
IBRX icon
IBRX
Immunitybio Inc
7.025 7.54B 113.29M -351.47M -309.19M -0.3898
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
435.76 111.45B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
758.73 80.54B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
747.26 46.32B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
330.72 42.29B 3.71B 313.75M 465.38M 2.2571
INSM icon
INSM
Insmed Inc
164.79 35.01B 606.42M -1.28B -997.58M -6.403

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-03-12 Fortgesetzt BTIG Research Buy
2025-05-20 Hochstufung Piper Sandler Neutral → Overweight
2025-03-06 Eingeleitet H.C. Wainwright Buy
2025-01-10 Eingeleitet BTIG Research Buy
2023-05-12 Herabstufung Piper Sandler Overweight → Neutral
2022-08-03 Eingeleitet Jefferies Buy
Alle ansehen

Immunitybio Inc Aktie (IBRX) Neueste Nachrichten

pulisher
09:59 AM

IBRX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com

09:59 AM
pulisher
08:37 AM

ImmunityBio Addresses FDA Warning on ANKTIVA Promotion - TipRanks

08:37 AM
pulisher
08:16 AM

ImmunityBio (IBRX) Stock Gains 3% Following FDA Compliance Response on Anktiva Marketing - Blockonomi

08:16 AM
pulisher
08:13 AM

ImmunityBio submits response to FDA OPDP, removes podcast and strengthens promotional compliance - TradingView

08:13 AM
pulisher
08:11 AM

ImmunityBio responds to FDA promotional compliance concerns By Investing.com - Investing.com India

08:11 AM
pulisher
08:03 AM

ImmunityBio (NASDAQ: IBRX) outlines response to FDA ad concerns - Stock Titan

08:03 AM
pulisher
07:58 AM

ImmunityBio (IBRX) Stock Climbs 3% After Firing Back at FDA Over Anktiva Ad Concerns - CoinCentral

07:58 AM
pulisher
07:32 AM

Immunitybio Addresses FDA Correspondence And Reaffirms Commitment To Advertising Compliance - TradingView

07:32 AM
pulisher
07:30 AM

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance - businesswire.com

07:30 AM
pulisher
03:49 AM

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

03:49 AM
pulisher
Apr 05, 2026

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Killeen Daily Herald

Apr 05, 2026
pulisher
Apr 05, 2026

IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits

Apr 05, 2026
pulisher
Apr 05, 2026

Securing Non-Dilutive Funding to Support Immunotherapy Platform Growth – ImmunityBio - Oncodaily

Apr 05, 2026
pulisher
Apr 05, 2026

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Black Hills Pioneer

Apr 05, 2026
pulisher
Apr 05, 2026

CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Downgrade) - Seeking Alpha

Apr 05, 2026
pulisher
Apr 04, 2026

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Snowflake Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Apr 04, 2026
pulisher
Apr 04, 2026

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - globenewswire.com

Apr 04, 2026
pulisher
Apr 04, 2026

ImmunityBio, Keysight, Rubrik, AFLAC, Moody’s Insider Shake-Up - TipRanks

Apr 04, 2026
pulisher
Apr 04, 2026

IBRX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - Morningstar

Apr 04, 2026
pulisher
Apr 04, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Apr 04, 2026
pulisher
Apr 04, 2026

INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit - Sahm

Apr 04, 2026
pulisher
Apr 04, 2026

Investors with Substantial Losses in ImmunityBio (IBRX) Have Opportunity to Lead Class Action Lawsuit - National Today

Apr 04, 2026
pulisher
Apr 03, 2026

INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit – Company AnnouncementFT.com - Financial Times

Apr 03, 2026
pulisher
Apr 03, 2026

IBRX INVESTOR ALERT: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PR Newswire

Apr 03, 2026
pulisher
Apr 03, 2026

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - PR Newswire

Apr 03, 2026
pulisher
Apr 03, 2026

Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - Carroll County Mirror-Democrat

Apr 03, 2026
pulisher
Apr 03, 2026

When a podcast becomes promotion: Inside the FDA’s warning shot at ImmunityBio - Medical Marketing and Media

Apr 03, 2026
pulisher
Apr 03, 2026

NYSE: PINS: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Pinterest, Inc. - GlobeNewswire Inc.

Apr 03, 2026
pulisher
Apr 03, 2026

ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline - PR Newswire

Apr 03, 2026
pulisher
Apr 03, 2026

ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Apr 03, 2026
pulisher
Apr 03, 2026

Jim Cramer on ImmunityBio: "I would encourage you to own it, provided you don’t own any other spec" - MSN

Apr 03, 2026
pulisher
Apr 03, 2026

ImmunityBio Sued for Securities Law Violations - National Today

Apr 03, 2026
pulisher
Apr 02, 2026

ImmunityBio Faces Investor Lawsuit Over Cancer Drug Claims - AD HOC NEWS

Apr 02, 2026
pulisher
Apr 02, 2026

ImmunityBio (IBRX) insider converts $25M note into 4.6M shares - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire Inc.

Apr 02, 2026
pulisher
Apr 02, 2026

ImmunityBio (NASDAQ:IBRX) Trading 2.2% HigherTime to Buy? - MarketBeat

Apr 02, 2026
pulisher
Apr 02, 2026

ImmunityBio: No Need To Rush Into Buying TodayWhy I'm Downgrading To Hold (NASDAQ:IBRX) - Seeking Alpha

Apr 02, 2026
pulisher
Apr 02, 2026

NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces - globenewswire.com

Apr 02, 2026
pulisher
Apr 02, 2026

IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein - globenewswire.com

Apr 02, 2026
pulisher
Apr 02, 2026

ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire

Apr 02, 2026
pulisher
Apr 02, 2026

IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of ... - Bluefield Daily Telegraph

Apr 02, 2026
pulisher
Apr 02, 2026

IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - ChartMill

Apr 02, 2026
pulisher
Apr 02, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire

Apr 02, 2026
pulisher
Apr 02, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Investors to Connect - ACCESS Newswire

Apr 02, 2026
pulisher
Apr 01, 2026

ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — Hagens Berman - Morningstar

Apr 01, 2026
pulisher
Apr 01, 2026

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm - Morningstar

Apr 01, 2026
pulisher
Apr 01, 2026

ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Caledonian Record

Apr 01, 2026
pulisher
Apr 01, 2026

ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. - globenewswire.com

Apr 01, 2026
pulisher
Apr 01, 2026

IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 01, 2026
pulisher
Apr 01, 2026

IBRX Investor Alert: ImmunityBio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Violated FDA Drug Rules: Levi & Korsinsky - PR Newswire

Apr 01, 2026
pulisher
Apr 01, 2026

IBRX stock notches strongest quarter ever — but these 2 smaller biotech plays ran even hotter - MSN

Apr 01, 2026

Finanzdaten der Immunitybio Inc-Aktie (IBRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Immunitybio Inc-Aktie (IBRX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Selecky Christobel
Director
Feb 23 '26
Option Exercise
2.98
25,000
74,500
25,000
Selecky Christobel
Director
Feb 23 '26
Sale
10.00
25,000
250,000
0
Sachs David C.
Chief Financial Officer
Feb 22 '26
Option Exercise
0.00
40,650
0
320,825
SOON-SHIONG PATRICK
See remarks
Feb 22 '26
Option Exercise
0.00
114,329
0
29,816,081
LAUER REGAN J
Chief Accounting Officer
Feb 22 '26
Option Exercise
0.00
4,065
0
117,548
Adcock Richard
CEO & President
Feb 22 '26
Option Exercise
0.00
152,439
0
637,904
Simon Barry J.
Director
Feb 22 '26
Option Exercise
0.00
15,243
0
3,096,847
Simon Barry J.
Director
Feb 23 '26
Sale
10.25
165,000
1,691,102
2,925,821
Simon Barry J.
Director
Feb 20 '26
Sale
9.25
10,000
92,500
3,081,604
$49.55
price down icon 1.90%
$28.34
price up icon 1.08%
$47.79
price down icon 1.05%
$91.15
price up icon 0.08%
ONC ONC
$311.43
price up icon 0.93%
$163.18
price down icon 1.52%
Kapitalisierung:     |  Volumen (24h):